Anti-NY-ESO-1 autoantibody may be a tumor marker for intrahepatic cholangiocarcinoma
Metrics: PDF 1643 views | HTML 1745 views | ?
Zhen Zhang1, Fan-Fan Li2, Ming-Dian Lu1, Shang-Xin Zhang1 and Yong-Xiang Li1
1Department of Gastrointestinal Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China
2Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
Yong-Xiang Li, email: [email protected]
Keywords: NY-ESO-1; antibody; intrahepatic cholangiocarcinoma; prognosis
Received: May 23, 2017 Accepted: October 28, 2017 Published: November 15, 2017
Anti-NY-ESO-1 antibody is observed in a multitude of malignancies. This study was aimed to evaluate the expression of serum anti-NY-ESO-1 antibodies and its prognostic value in intrahepatic cholangiocarcinoma. A total of 103 patients with intrahepatic cholangiocarcinoma were enrolled in the study. Enzyme-linked immunosorbent assay (ELISA) was performed to detect the serum level of anti-NY-ESO-1 antibody. Western blotting was performed to assess the NY-ESO-1 expression in tumor and adjacent tissues. The serum NY-ESO-1 antibody was detected in 18.4% of patients with intrahepatic cholangiocarcinoma, a value that was significantly higher than that in patients with chronic Hepatitis B. Serum NY-ESO-1 antibody was positively correlated with tumor differentiation, lymphatic metastasis, cTNM stage and abdominal pain. Finally, there was a higher cumulative survival rate in patients with serum NY-ESO-1 positivity than in those with serum NY-ESO-1 negativity among the patients with stage III + IV. Our data uncovered that NY-ESO-1 antibody might be a helpful tumor marker and prognostic predictor in intrahepatic cholangiocarcinoma.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.